Ortho Regenerative Technologies has submitted requested data related to its Ortho-R drug to the FDA after the company paused its clinical trial.

Vivex Biologics launched its Via Mend synthetic bone fillers, a line of bone graft substitutes, the company announced July 15.

Since launching its initial public offering in February, orthobiologics company Bioventus marked several notable achievements, including a multimillion-dollar acquisition.

Durham, N.C.-based Bioventus has launched a new allograft substitute product, Osteoamp Select Flowable, the company said July 13.

Orthopedic device company RTI Surgical partnered with Exactech to develop and supply biologic bone grafts.

Orthopedic surgeon Scott Rodeo, MD, of New York City-based Hospital for Special Surgery received a $50,000 grant from the Orthopaedic Research and Education Foundation to study an injectable knee biologic.

Lawsuits on behalf of a Florida woman and a Delaware man were filed against Aziyo Biologics after they received a tainted FiberCel implant.

Orthopedic device company Arthrex struck a deal with Celularity to distribute biomaterial products for orthopedic surgery, according to a July 1 news release.

The number of patients treated for tuberculosis after undergoing spine surgery with FiberCel, a bone matrix allograft, is growing.

Ortho Regenerative Technologies named Howard Walthall and Tim Cunningham to its board of directors, the company said June 15.

The FDA is ramping up enforcement activities against companies developing unapproved stem cell therapies, particularly for spine and orthopedic indications, according to the Regulatory Affairs Professional Society.

Ortho Regenerative Technologies received a clinical hold letter from the FDA related to its trial for its hybrid implant, Ortho-R, the company said June 4.

Adipose cells, commonly known as fat, could be a useful source of stem cells to promote bone growth in spinal fusion, according to researchers from Johns Hopkins Medicine in Baltimore.

The FDA has granted breakthrough device designation for Cerapedics' P-15L bone graft for the treatment of degenerative disc disease.

DiscGenics, a biopharmaceutical company focused on regenerative therapies for spinal conditions, has finished enrolling patients in its Japanese study of  IDCT, an allogeneic, injectable disc cell therapy for lumbar disc degeneration.

Pacira Biosciences invested $3 million in Spine BioPharma.

Rishi Wadhwa, MD, of Shreveport, La.-based Specialists Hospital, completed the first implantation of Ventris Medical's Allocell AF allograft.

Orthobiologics company Kuros Biosciences has treated the first patient in a clinical trial comparing MagnetOs Putty to autograft for posterolateral spinal fusion.

The first two spinal surgery cases with TheraCell's TheraFuze DBF Fiber Bag were completed in Illinois and Texas.

Two professors from West Lafayette, Ind.-based Purdue University developed a shoulder implant that uses a patient's stem cells to help repair the rotator cuff.